Decreases in prostate volume over time and resulting changes in PSA performance may have contributed to the detection of high-grade prostate cancer in the finasteride group of the PCPT. Medscape Medical News
Acute myeloid leukemia is a challenging disease to treat, but new molecular and cytogenetic markers can help clinicians guide patients to more effective and safe therapy. The current article reviews these markers and offers strategies for their clinical application. Journal of the National Comprehensive Cancer Network